Karen Jean Ferrante
Independent DirectorDr. Karen Jean Ferrante, B. Sc., M. D., served as Independent Non-Executive Director at Hutchison Whampoa Limited until May 12, 2023. She served as Member of Scientific Advisory Board at Trillium Therapeutics Inc. since November 2020 until its acquisition by Pfizer in November 2021. She has been an Independent Director of Cogent Biosciences, Inc. (formerly known as Unum Therapeutics Inc.) since February 2018. Dr. Ferrante served as the Chief Medical Officer of Tokai Pharmaceuticals, Inc. since April 15, 2014 until August 31, 2016 and served as its Head of Research & Development from April 15, 2014 to March 2016. She served as the Chief Medical Officer of Millennium Pharmaceuticals, Inc. She served at The Takeda Oncology Company as the Head of Takeda’s Oncology Therapeutic Area. From 2007 to July 2013, she served as senior positions at Millennium Pharmaceuticals and its parent company, Takeda Pharmaceuticals and served as Oncology Therapeutic Area and Cambridge USA Site Head from May 2013 to July 2013. From 1999 to 2007, she served in Global Research and Development at Pfizer and served as Vice President of Global Research and Development and therapeutic area clinical leader in Oncology Development since 2007. Dr. Ferrante previously held positions of increasing responsibility at Pfizer Global Research and Development and Bristol-Myers Squibb. Dr. Ferrante began her career in the pharmaceutical industry as Associate Director of Clinical Oncology at Bristol-Myers Squibb Company in 1995. While at the Beth Israel Deaconess Hospital, she served as Clinical Instructor at the Harvard Medical School. She had been a Member of Scientific Advisory Board at Kazia Therapeutics Limited since September 5, 2016 until July 2022. She had been an Independent Non-Executive Director at HUTCHMED (China) Limited (formerly known as Hutchison China MediTech Limited) since February 1, 2017 until May 12, 2023. Dr. Ferrante served as Independent Co-Chair of the Board at Progenics Pharmaceuticals, Inc. since October 2019 until November 2019 and had been its Independent Director since January 30, 2014 until June 19, 2020. She served as Independent Director at MacroGenics, Inc. since January 25, 2017 until September 01, 2026. She served as a Director of Baxalta Incorporated from July 27, 2015 to June 3, 2016. She is a Director at Hutchinson China MediTech Limited. She served at the New England Deaconess Hospital in Boston (Beth Israel Deaconess), where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. She has authored numerous papers in the field of oncology, is an active participant in academic and professional associations and symposia and holds several patents. From 1988 to 1991, she pursued her clinical fellowship at the New England Deaconess Hospital, a teaching hospital of Harvard Medical School. Dr. Ferrante holds a B. S. in Chemistry and Biology from Providence College in 1980 and an M. D. from Georgetown University in 1988.
Positions
- Company NameCogent Biosciences, Inc.Stock CodeCOGTPositionIndependent DirectorColleagues
- ARAndrew R. RobbinsPresident, CEO & Director
- PEPeter Evan HarwinIndependent Chairman of the Board
- JLJohn L. GreenCFO & Principal Accounting Officer
- JEJohn Edward RobinsonChief Scientific Officer
- JSJessica SachsChief Medical Officer
- CPCole PinnowChief Commercial Officer
- AMArlene M. MorrisIndependent Director
- TETodd E. ShegogIndependent Director
